Phase 3
N=357
Aurinia Renal Response in Active Lupus With Voclosporin
Lupus Nephritis
Bottom Line
View on ClinicalTrials.gov: NCT03021499 ↗Enrolled (actual)
357
Serious AEs
21.1%
Results posted
Jun 2021
Primary outcome: Primary: Number of Participants With Adjudicated Renal Response at Week 52 — 73; 40; 106; 138 Participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Voclosporin (Drug); Placebo Oral Capsule (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Aurinia Pharmaceuticals Inc.
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adjudicated Renal Response at Week 52 |
73; 40; 106; 138 | <0.001 sig |
| SECONDARY Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less |
116; 78; 63; 100 | <0.001 sig |
| SECONDARY Time to Urine Protein Creatinine Ratio of ≤0.5 mg/mg (Number of Days) |
169; 372 | — |
| SECONDARY Number of Participants With Renal Response at Week 24 |
58; 35; 121; 143 | 0.002 sig |
| SECONDARY Number of Subjects With Partial Renal Response at Weeks 24 & 52 |
126; 89; 125; 92 | <0.001 sig |
| SECONDARY Number of Subjects Achieving, and Remaining in, Renal Response (Urine Protein Creatinine Ratio ≤0.5 mg/mg) |
116; 78; 53; 37; 63; 41 | 0.349 |
| SECONDARY Duration of Renal Response (Number of Days) |
216; 198 | — |
| SECONDARY Number of Subjects Achieving 50% Reduction in Urine Protein Creatinine Ratio |
173; 135; 6; 43 | — |
| SECONDARY Time to 50% Reduction in UPCR (Number of Days) |
29; 63 | <0.001 sig |
| SECONDARY Change From Baseline in eGFR |
78.3; 77.4; -1.5; 3.3; -0.4; 3.2 | < 0.001 sig |
| SECONDARY Change From Baseline in UPCR |
4.14; 3.87; -1.46; -0.7; -1.98; -1.07 | 0.011 sig |
| SECONDARY Number of Subjects With Renal Response With Low Dose Steroids |
32; 16; 64; 36 | 0.008 sig |
| SECONDARY Change From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA - SLEDAI) |
-4.5; -4.1; -6; -5.5 | 0.373 |
| SECONDARY Change From Baseline in Patient Reported Outcomes |
6.64; 7.11; 10.44; 10.81; 7.7; 6.06 | 0.733 |
Summary
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.
Eligibility Criteria
Key Inclusion Criteria
- Subjects with evidence of active nephritis, defined as follows:
- Kidney biopsy result within 2 years prior to screening indicating Class III, IV-S, IV-G (alone or in combination with Class V), or Class V LN with a doubling or greater increase of UPCR within the last 6 months to a minimum of ≥1.5 mg/mg for Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy results over 6 months prior to screening must be reviewed with a medical monitor to confirm eligibility.
OR
- Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S or IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at screening.
OR
- Kidney biopsy result within 6 months prior to screening indicating Class V LN and a UPCR of ≥2 mg/mg at screening.
- Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
Exclusion Criteria
- Estimated glomerular filtration rate (eGFR) of ≤45 mL/minute at screening.
- Current or medical history of:
- Congenital or acquired immunodeficiency.
- In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.
- Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.
- Lymphoproliferative disease or previous total lymphoid irradiation.
- Severe viral infection or known HIV infection.
- Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
- Other known clinically significant active medical conditions, such as:
- Severe cardiovascular disease, liver dysfunction or chronic obstructive pulmonary disease or asthma requiring oral steroids or any other overlapping autoimmune condition for which the condition or the treatment of the condition may affect the study assessments or outcomes.
Data sourced from ClinicalTrials.gov (NCT03021499). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.